Abstract
Endothelial inflammation is a multifaceted physiological process that plays a pivotal role in the pathogenesis and progression of diverse diseases, encompassing but not limited to acute lung infections like COVID-19, coronary artery disease, stroke, sepsis, metabolic syndrome, certain malignancies, and even psychiatric disorders such as depression. This inflammatory response is characterized by augmented expression of adhesion molecules and secretion of pro-inflammatory cytokines. In this study, we discovered that saponins from Allium macrostemon bulbs (SAMB) effectively inhibited inflammation in human umbilical vein endothelial cells induced by the exogenous inflammatory mediator lipopolysaccharide or the endogenous inflammatory mediator tumor necrosis factor-α, as evidenced by a significant reduction in the expression of pro-inflammatory factors and vascular cell adhesion molecule-1 (VCAM-1) with decreased monocyte adhesion. By employing the NF-κB inhibitor BAY-117082, we demonstrated that the inhibitory effect of SAMB on VCAM-1 expression may be attributed to the NF-κB pathway’s inactivation, as characterized by the suppressed IκBα degradation and NF-κB p65 phosphorylation. Subsequently, we employed a murine model of lipopolysaccharide-induced septic acute lung injury to substantiate the potential of SAMB in ameliorating endothelial inflammation and acute lung injury in vivo. These findings provide novel insight into potential preventive and therapeutic strategies for the clinical management of diseases associated with endothelial inflammation.
Funding Information
  • National Natural Science Foundation of China (82160051, 82160791, 82104180, 20212BAB206008, 20232BAB206156, 20202BCD42014, TQ-27, ZXYYLXK20220103)
  • Jiangxi Provincial Natural Science Foundation (82160051, 82160791, 82104180, 20212BAB206008, 20232BAB206156, 20202BCD42014, TQ-27, ZXYYLXK20220103)
  • Jiangxi Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Vascular Remodeling Associated Diseases (82160051, 82160791, 82104180, 20212BAB206008, 20232BAB206156, 20202BCD42014, TQ-27, ZXYYLXK20220103)
  • Construction Project of Pharmacy Special Zone (New Drug Creation) in Jiangxi University of Chinese Medicine (82160051, 82160791, 82104180, 20212BAB206008, 20232BAB206156, 20202BCD42014, TQ-27, ZXYYLXK20220103)
  • Top Discipline of Jiangxi Province and Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine (82160051, 82160791, 82104180, 20212BAB206008, 20232BAB206156, 20202BCD42014, TQ-27, ZXYYLXK20220103)

This publication has 47 references indexed in Scilit: